Evidence map›Paper›PMID 33836772›Full record

ArticleMalaria journal2021

Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study.

Ayleen Kosasih, Cristian Koepfli, M Sopiyudin Dahlan, William A Hawley, J Kevin Baird, Ivo Mueller, Neil F Lobo, Inge Sutanto

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Malaria journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01878357 (Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01878357 phase4completednot on this map

Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial

TypeinterventionalSponsorIndonesia UniversityRan2013 to 2013Enrolled1,488ConditionsMalariaArmsdihydroartemisinin-piperaquine, primaquine
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Biology and epidemiology ofParasite epidemiology and control · 2023
    Review
  6. Article
  7. Article
  8. Frontiers in cellular and infection microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 4 countries.

Ayleen KosasihPhD Programme in Biomedical Sciences, Medical Faculty, Universitas Indonesia, Jakarta, Indonesia.
Cristian KoepfliEck Institute for Global Health, University of Notre Dame, Notre Dame, IN, USA.
M Sopiyudin DahlanPT Epidemiologi Indonesia, Jakarta, Indonesia.
William A HawleyUNICEF, Jakarta, Indonesia.
J Kevin BairdCenter for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Ivo MuellerInfection & Immunity Division, Walter & Eliza Hall Institute, Melbourne, Australia.
Neil F LoboEck Institute for Global Health, University of Notre Dame, Notre Dame, IN, USA.
Inge SutantoIndonesian Medical Education and Research Institute, Jakarta, Indonesia. sutanto.inge@yahoo.com.ORCID http://orcid.org/0000-0003-2488-5133
University of Notre Dame · USEijkman Institute for Molecular Biology · IDIndonesian Orthopaedic Association · IDUniversity of Indonesia · IDUniversity of Oxford · GBWalter and Eliza Hall Institute of Medical Research · AUWWF-Indonesia · ID

Funding

Bill and Melinda Gates Foundation 45114Kementerian Riset Teknologi Dan Pendidikan Tinggi Republik Indonesia 120/SP2H/PTNBH/DRPM/2018
6 · The paper itself

Abstract

backgroundA goal of malaria epidemiological interventions is the detection and treatment of parasite reservoirs in endemic areas-an activity that is expected to reduce local transmission. Since the gametocyte is the only transmissible stage from human host to mosquito vector, this study evaluated the pre and post presence of gametocytes during a mass screening and treatment (MST) intervention conducted during 2013 in East Nusa Tenggara, Indonesia.

methodsRT-qPCR targeting pfs25 and pvs25 transcripts-gametocyte molecular markers for Plasmodium falciparum and Plasmodium vivax, respectively, was performed to detect and quantify gametocytes in blood samples of P. falciparum and P. vivax-infected subjects over the course of the MST study. The presence of both asexual and sexual parasites in microscopic and submicroscopic infections was compared from the start and end of the MST, using proportion tests as well as parametric and non-parametric tests.

resultsParasite prevalence remained unchanged for P. falciparum (6% = 52/811 versus 7% = 50/740, p = 0.838), and decreased slightly for P. vivax (24% = 192/811 versus 19% = 142/740, p = 0.035) between the MST baseline and endpoint. No significant difference was observed in gametocyte prevalence for either P. falciparum (2% = 19/803 versus 3% = 23/729, p = 0.353, OR = 1.34, 95%CI = 0.69-2.63), or P. vivax (7% = 49/744 versus 5% = 39/704, p = 0.442, OR = 0.83, 95%CI = 0.52-1.31). Even though there was an insignificant difference between the two time points, the majority of parasite positive subjects at the endpoint had been negative at baseline (P. falciparum: 66% = 29/44, P. vivax: 60% = 80/134). This was similarly demonstrated for the transmissible stage-where the majority of gametocyte positive subjects at the endpoint were negative at baseline (P. falciparum: 95% = 20/21, P. vivax: 94% = 30/32). These results were independent of treatment provided during MST activities. No difference was demonstrated in parasite and gametocyte density between both time points either in P. falciparum or P. vivax.

conclusionIn this study area, similar prevalence rates of P. falciparum and P. vivax parasites and gametocytes before and after MST, although in different individuals, points to a negligible impact on the parasite reservoir. Treatment administration based on parasite positivity as implemented in the MST should be reevaluated for the elimination strategy in the community. Trial registration Clinical trials registration NCT01878357. Registered 14 June 2013, https://www.clinicaltrials.gov/ct2/show/NCT01878357.

Indexed as

Mass ScreeningAdolescentAdultAgedAged, 80 and overCarrier StateChildChild, PreschoolFemaleHumansIndonesiaInfantLongitudinal StudiesMalaria, FalciparumMalaria, VivaxMaleGametocyteMass screening and treatmentPfs25Pvs25

Identifiers

PMID33836772
PMCPMC8034167
OpenAlexW3109470457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.